MRP as a new predictive marker of tamoxifen efficiency in treatment of estrogen receptor-positive breast cancer.
Bogush
T A
TA
N.N. Blokhin Russian Cancer Research Center of the Russian Academy of Medical Sciences, Kashirskoe sh. 24, Moscow, 115478 Russia.
Dudko
E A
EA
Bogush
E A
EA
Tikhomirov
M V
MV
Yu Kirsanov
V
V
Davydov
M I
MI
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000276:immunology / Q000378:metabolism*; D000818:Animals; D000906:Antibodies / Q000276:immunology; D000918:Antibody Specificity; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000276:immunology / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D005260:Female; D006367:HeLa Cells; D006801:Humans; D011960:Receptors, Estrogen / Q000378:metabolism*; D013194:Staining and Labeling; D013629:Tamoxifen / Q000494:pharmacology* / Q000627:therapeutic use*
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000906:Antibodies; D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D011960:Receptors, Estrogen; D013629:Tamoxifen